1741P Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial

G.A De Velasco Oria,I García-Carbonero,E Esteban-Gonzalez,A Pinto,D Lorente,A Gómez De Liaño,E Martínez Ortega,L Jimenez Colomo,J Puente,I Gonzalez,O Fernández,G Anguera

doi:10.1016/j.annonc.2022.07.1819

1741P Atezolizumab (ATZ) with split-doses of cisplatin plus gemcitabine in patients with locally advanced or metastatic urothelial carcinoma (SOGUG-AUREA): A multicentre, single-arm phase II trial

G.A De Velasco Oria, I García-Carbonero + Show 10 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1819

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Hospital Universitario 12 De Octubre, Hospital Virgen de la Salud, Central University Hospital of Asturias, Hospital Universitario La Paz, Fundación Hospital Provincial de Castellón, Complexo Hospitalario Universitario A Coruña, Complejo Hospitalario de Jaén, Institut Català d'Oncologia, Hospital Clínico San Carlos, Hospital Son Llatzer, Hospital de Sant Pau

#Split-dose Cisplatin #Single-agent Monotherapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Split-dose cisplatin plus gemcitabine is an alternative for combinations with immunotherapy in unfit patients for full doses of cisplatin. The combination of split-dose cisplatin with ATZ might be a feasible treatment that could provide better outcomes than single-agent monotherapy or carboplatin combinations.

Full Text